Archives

Fesarius Therapeutics demonstrates the science that establishes DermiSphere™ hDRT in a class of its own

B NEW YORK, April 30, 2026 /PRNewswire/ — FesariusTherapeutics, Inc., a commercial stage bioregenerative technology company focused on the development, manufacture and commercialization of solutions… Login to continue reading Login…

Read MoreFesarius Therapeutics demonstrates the science that establishes DermiSphere™ hDRT in a class of its own

START Research Expands Clinical Leadership with Appointment of Dr. Neel Belani as Clinical Investigator at START New Jersey

B Strengthening clinical research capabilities in one of the nation’s most densely populated and high-opportunity oncology markets EAST BRUNSWICK, N.J., April 30, 2026 /PRNewswire/ —… Login to continue reading Login…

Read MoreSTART Research Expands Clinical Leadership with Appointment of Dr. Neel Belani as Clinical Investigator at START New Jersey

Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio

B – FORZINITY™ (elamipretide) injection early commercial momentum demonstrates strong patient uptake and rapid access timelines – – Advancing differentiated mitochondrial-targeted pipeline across rare and… Login to continue reading Login…

Read MoreStealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

B – Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the… Login to continue reading Login…

Read MoreBambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis